Torrance, CA, United States of America

Michael David Mattie

USPTO Granted Patents = 1 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael David Mattie: Innovator in Chimeric Antigen Receptor T Cell Therapy

Introduction

Michael David Mattie is a prominent inventor based in Torrance, CA (US). He is known for his significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptor T cell therapy. His innovative work aims to improve treatment options for patients with malignancies.

Latest Patents

Michael David Mattie holds 1 patent related to his groundbreaking work. His patent focuses on methods of treating malignancies through the administration of genetically modified T cell immunotherapy. The disclosure outlines effective dosing strategies and manufacturing methods for this type of immunotherapy. Additionally, it includes methods for assessing a patient's response to treatment based on specific attributes measured before and after therapy.

Career Highlights

Mattie is currently associated with Kite Pharma, Inc., a leading company in the field of cell therapy. His role at Kite Pharma allows him to collaborate with other experts in the industry and contribute to the advancement of cancer treatment methodologies. His work is pivotal in pushing the boundaries of what is possible in immunotherapy.

Collaborations

One of his notable coworkers is Adrian I Bot, with whom he collaborates on various projects related to T cell therapies. Their combined expertise enhances the research and development efforts at Kite Pharma.

Conclusion

Michael David Mattie's innovative contributions to chimeric antigen receptor T cell therapy represent a significant advancement in cancer treatment. His work continues to inspire and pave the way for future developments in immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…